[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1979

Panacea or Placebo?

Author Affiliations

Davenport, IA

Arch Intern Med. 1979;139(6):714. doi:10.1001/archinte.1979.03630430090032

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  The editorial by Dr Richard W. Welch, in the Archives (138:1208-1209, 1978), very appropriately indicated the narrow spectrum of proved clinical usefulness of cimetidine.Without any intention of detracting from this editorial opinion, I would suggest that under certain circumstances there may be other very narrow indications for the use of cimetidine, at least in the practice of hematology and oncology. Certain patients in this field require high-dose corticosteroid therapy, and yet may have either an active ulcer or a history of a recurrent active ulcer. Under these circumstances, I think that cimetidine in the usual doses, for the period that the patient is receiving corticosteroids, is a major benefit and allows the use of the corticosteroids; otherwise, they might be absolutely contraindicated.I would invite other comments from hematologists and oncologists who are faced with this situation; at least at present, I have been unwilling to

First Page Preview View Large
First page PDF preview
First page PDF preview